Chromic Chloride

drug
On this page

Also known as Chromic chloride anhydrousChromic chloride hexahydrateChromium (as chromic chloride)Chromium (iii) chlorideChromium chloride (crcl3)Chromium(iii) chloride, anhydrousChromium(III) Chloride

Summary

Chromic Chloride (CHEMBL1200528) is an approved small molecule.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1200528
NameChromic Chloride
TypeSmall molecule
Max phase4

Also known as: Chromic chloride, Chromic chloride anhydrous, Chromic chloride hexahydrate, Chromium (as chromic chloride), Chromium (iii) chloride, Chromium chloride (crcl3), Chromium(iii) chloride, anhydrous, CHROMIC CHLORIDE, Chromium(III) Chloride

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Tyrosine-protein kinase Fyn, Epidermal growth factor receptor.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
FYN5.76IC501750nMCHEMBL_ACT_7679920
EGFR5.53IC502955nMCHEMBL_ACT_7679918

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.